The clinical trial “Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called De-differentiated Liposarcoma” is testing another MDM2 inhibitor versus doxorubicin chemotherapy. The gene discussed is MDM2; the disease is liposarcoma.